Glutamate neurocircuitry: Theoretical underpinnings in: Schizophrenia

Frontiers in Pharmacology

Volumn 3 NOV, Issue , 2012, Pages

  Schwartz, Thomas L ^a   Sachdeva, Shilpa ^a   Stahl, Stephen M ^b,c  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Dopamine hypothesis; Glutamate hypothesis; NMDA receptor; Schizophrenia

Indexed keywords

AMPA RECEPTOR; CYCLOSERINE; GLUTAMATE RECEPTOR 2 AGONIST; GLUTAMATE RECEPTOR 3 AGONIST; GLUTAMATE RECEPTOR AGONIST; GLUTAMIC ACID; GLYCINE RECEPTOR AGONIST; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NEU DIFFERENTIATION FACTOR; OLANZAPINE; PLACEBO; SARCOSINE; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR DISTRIBUTION; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; G72 GENE; GABAERGIC SYSTEM; GENETIC SUSCEPTIBILITY; GRIN1 GENE; HUMAN; INTERNEURON; INTRACELLULAR SIGNALING; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; MUTATOR GENE; NERVE CELL NETWORK; NERVE CONDUCTION; NEUROANATOMY; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; SCHIZOPHRENIA;

EID: 84870736284     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00195     Document Type: Article

References (54)

1. Begni, S., Popoli, M., Moraschi, S., Big-notti, S., Tura, G. B., and Gennarelli, M. (2002). Association between the ionotropic gultamate receptor kainate 3 (GRIK3) ser310ala polymorphism and schizophrenia. Mol. Psychiatry 7, 416-418.
2. Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., et al. (2007). The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164, 1593-1602.
3. Carlsson, A., Waters, N., and Carls-son, M. L. (1999). Neurotransmitter interactions in schizophrenia: therapeutic implications. Biol. Psychiatry 46, 1388-1395.
4. Chaves, C., Marque, C. R., Trzes-niak, C., Machado de Sousa, J. P., Zuardi, A. W., Crippa, J. A., et al. (2009). Glutamate-n-methyl-d-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia. Braz. J. Med. Biol. Res. 42, 1002-1014.
5. Chen, X., Dunham, C., Kendler, S., Wang, X., O'Neill, F. A., Walsh, D., et al. (2004). Regulator of G-protein signaling 4 (RGS4) gene is associated with schizophrenia in Irish high density families. Am. J. Med. Genet. B Neuropsychiatr. Genet. 129, 23-26.
6. Chumakov, I., Blumenfield, M., Gueras-simenko, O., Cavarec, L., Pali-cio, M., Abderrahim, H., et al. (2002). Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 99, 13675-13680.
7. Dean, O., Giorlando, F., and Berk, M. (2011). N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci. 36, 78-86.
8. Deutsch, S. I., Rosse, R. B., Schwartz, B. L., Fay-McCarthy, M., Rosenberg, P. B., and Fearing, K. (1997). Methyl-ene blue adjuvant therapy of schizophrenia. Clin. Neuropharmacol. 20, 357-363.
9. Emamian, E. S., Hall, D., Birnbaum, M. J., Karayiorgou, M., and Gogos, J. A. (2004). Convergent evidence for impaired AKT1- GSK3beta signaling in schizophrenia. Nat. Genet. 36, 131-137.
10. EmDevon, R. S., Anderson, S., and Teague, P. W. (2001). The genomic organization of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol. Psychiatry 6, 311-314.
11. Erhardt, S., Olsson, S. K., and Eng-berg, G. (2009). Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 23, 91-101.
12. Fischbach, G. D., and Rosen, K. M. (1997). ARIA: a neuromuscu-lar junction neuregulin. Annu. Rev. Neurosci. 20, 429-458.
13. Furukawa, H., Singh, S. K., Man-cusso, R., and Gouaux, E. (2005). Subunit arrangement and function in NMDA receptors. Nature 438, 185-192.
14. Gerber, D. J., Hall, D., Miyakawa, T., Demars, S., Gogos, J. A., Karayior-gou, M., et al. (2003). Evidence for association of schizophrenia with genetic variation in the 8p213 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc. Natl. Acad. Sci. U.S.A. 100, 8993-8998.
15. Hahn, C. G., Wang, H. Y., Cho, D. S., Talbot, K., Gur, R. E., Berret-tini, W. H., et al. (2006). Altered neuregulin I-erbB4 signaling contributes to NMDA receptor hypo-function in schizophrenia. Nat. Med. 12, 824-828.
16. Halene, T. B., Ehrlichman, R. S., Liang, Y., Christian, E. P., Jonak, G. J., Gur, T. L., et al. (2009). Assessment of NMDA receptor NR1 subunit hypo-function in mice as a model for schizophrenia. Genes Brain Behav. 8, 661-675.
17. Hollmann, M., and Heinemann, S. (1994). Cloned glutamate receptors. Annu. Rev. Neurosci. 17, 31-108.
18. Kinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., et al. (2011). A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J. Clin. Psychiatry 31, 349-355.
19. Kiss, T., Hoffmann, W. E., Scott, L., Kawabe, T. T., Milici, A. J., Nilsen, E. A., et al. (2011). Role of thalamic projection in NMDA receptor-induced disruption of cortical slow oscillation and short-term plasticity. Front. Psychiatry 4:14. doi:10.3389/fpsyt.2011.00014
20. Lane, H. Y., Lin, C. H., Huang, Y. J., Liao, C. H., Chang, Y. C., Tsai, G. E., et al. (2010). A randomized, double-blind, placebo-controlled comparison study of sar-cosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharma-col. 13, 451-460.
21. Loftis, J. M., and Janowsky, A. (2003). The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 97, 55-85.
22. Maia de Oliveira, J. P., Lobão, B., Machado-de-Sousa, J. P., Baker, G. B., Dursun, S., and Hallak, J. E. C. (2011). Targeting the NMDA receptor nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia. Rev. Bras. Psiquiatr. 33, 223-224.
23. McClintock, W., Shannon Weickert, C., Halim, N. D., Lipska, B. K., Hyde, T. M., Herman, M. M., et al. (2003). Reduced Expression of Dys-bindin Protein in the Dorso-Lateral Prefrontal Cortex of Patients with Schizophrenia. Program No. 317.9. 2003 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience.
24. Meltzer, H. Y., and Stahl, S. M. (1976). The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull. 2, 19-76.
25. Miyakawa, T., Leiter, L. M., Gerber, D. J., Gainetdinov, R. R., Sotnikova, T. D., Zeng, H., et al. (2003). Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 100, 8987-8992.
26. Miyamoto, Y., Yamada, K., Noda, Y., Mori, H., Mishina, M., Nabeshima, T., et al. (2001). Hyperfunction of dopaminergicand serotonergic neu-ronal systems in micelacking the NMDA receptor epsilon1 subunit. J. Neurosci. 21, 750-757.
27. Mohn, A. R., Gainetdinov, R. R., Caron, M. G., and Koller, B. H. (1999). Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98, 427-436.
28. Mohrmann, R., Hatt, H., and Gottmann, K. (2000). Developmental regulation of subunit composition of extrasynaptic NMDA receptors in neocorti-cal neurons. Neuroreport 11, 1203-1208
29. Morita, Y., Ujike, H., Tanaka, Y., Otani, K., Kishimoto, M., Morio, A., et al. (2007). A genetic variant of the ser-ine racemase gene is associated with schizophrenia. Biol. Psychiatry 61, 1200-1203.
30. Moriyoshi, K., Masu, M., Ishii, T., Shige-moto, R., Mizuno, N., and Nakan-ishi, S. (1991). Molecular cloning and characterization of the rat NMDA receptor. Nature 354, 31-37.
31. Morris, D. W., Rodgers, A., McGhee, K. A., Schwaiger, S., Scully, P., Quinn, J., et al. (2004). Confirming RGS4 as a susceptibility gene for schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 125, 50-53.
32. Nakanishi, S., and Masu, M. (1994). Molecular diversity and functions of glutamate receptors. Annu. Rev. Biophys. Biomol. Struct. 23, 319-348.
33. Opler, L. A., and Opler, M. G. (2012). "Antipsychotics: where have we been? Where are we now? Where are we going?," in Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention, eds T. L. Schwartz, J. Megna, and M. Topel (New York: Nova Scientific Press) (in press).
34. Ozaki, M., Sasner, M., Yano, R., Lu, H. S., and Buonanno, A. (1997). Neuregulin-beta induces expression of an NMDA-receptor subunit. Nature 390, 691-694.
35. Patil,S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., et al. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat. Med. 13, 1102-1107.
36. Qin, S., Zhao, X., Pan, Y., Liu, J., Feng, G., Fu, J., et al. (2005). An association study of the N-methyl-d-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray. Eur. J. Hum. Genet. 13, 807-814.
37. Reif, A., Schecklmann, M., Eirich, E., Jacob, C. P., Jarczok, T. A., Kittel-Schneider, S., et al. (2011). A functional promoter polymorphism of neuronal nitric oxide synthase moderates prefrontal functioning in schizophrenia. Int. J. Neuropsy-chopharmacol. 14, 887-897.
38. Sadock, B. J., and Sadock, V. (2003). Kaplan and Sadock's Synopsis of Psychiatry, 9th Edn. Philadelphia: Lip-pincott Williams and Wilkins.
39. Schwartz, T. L., Sachdeva, S., and Stahl, S. M. (2012). Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia. Curr. Pharm. Des. 18, 1580-1592.
40. Sobolevsky, A. I., Rooney, L., and Woll-muth,L.P. (2002). Staggeringof sub-units in NMDAR channels. Biophys. J. 83, 3304-3314.
41. Stahl, S. M. (2007a). Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectr. 12, 265-268.
42. Stahl, S. M. (2007b). The genetics of schizophrenia converge upon the NMDA glutamate receptor. CNS Spectr. 12, 583-588.
43. Stahl, S. M. (2008). Essential Psy-chopharmacology, 3rd Edn. New York, NY: Cambridge University Press.
44. Stahl, S. M. (in press). Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 4th Edn. Cambridge University Press.
45. Stefansson, H., Sarginson, J., Kong, A., Yates, P., Steinthorsdottir, V., Gudfinnsson, E., et al. (2003). Association of neuregulin-1 with schizophrenia confirmed in a Scottish population. Am. J. Hum. Genet. 72, 83-87.
46. Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdot-tir, S., Sigmundsson, T., Ghosh, S., et al. (2002). Neuregulin-1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71, 877-892.
47. Straub, R. E., and Weinberger, D. R. (2006). Schizophrenia genes: famine to feast. Biol. Psychiatry 60, 81-83.
48. Talbot, K., Eidem, W. L., Tinsley, C. L., Benson, M. A., Thompson, E. W., Smith,R. J.,et al. (2004). Dysbindin-1 is reduced in intrinsic, glutamater-gic terminals of the hippocampal formation in schizophrenia. J. Clin. Invest. 113, 1353-1363.
49. Tang, J., Chen, X., Xu, X., Wu, R., Zhao, J., Hu, Z., et al. (2006). Significant linkage and association between a functional (GT)n polymorphism in promoter of the N-methyl-d-aspartate receptor subunit gene (GRIN2A) and schizophrenia. Neurosci. Lett. 409, 80-88.
50. Tsai, G., Lane, H. Y., Yang, P., Chong, M. Y., and Lange, N. (2004). Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 55, 452-456.
51. Tsai, G. E., and Lin, P. Y. (2010). Strategies to enhance n-methyl-d-aspartate receptor-mediated neuro-transmission in schizophrenia, a critical review and meta-analysis. Curr. Phar. Des. 16, 522-537.
52. Watanabe, M., Inoue, Y., Sakimura, K., and Mishina, M. (1993). Distinct spatio-temporal distributions of the NMDA receptor channel subunit mRNAsinthe brain.Ann. N.Y. Acad. Sci. 707, 463-466.
53. Wezenberg, E., Verkes, R. J., Ruigt, G. S., Hulstijn,W.,and Sabbe,B. G. (2007). Acute effectsof the ampakine faram-pator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology 32, 1272-1283.
54. Williams, N. M., Bowen, T., Spur-lock, G., Norton, N., Williams, H. J., Hoogendoorn, B., et al. (2002). Determination of the genomic structure and mutation screening in schizophrenic individuals for five subunits of the N-methyl-D-aspartate glutamate receptor. Mol. Psychiatry 7, 508-514.